Galapagos Stock (NASDAQ:GLPG)


ForecastOwnershipChartTranscripts

Previous Close

$27.51

52W Range

$24.74 - $37.78

50D Avg

$30.32

200D Avg

$32.15

Market Cap

$1.84B

Avg Vol (3M)

$187.56K

Beta

0.30

Div Yield

-

GLPG Company Profile


Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

BE

Employees

452

IPO Date

Feb 27, 2012

Website

GLPG Performance


Latest Earnings Call Transcripts


Q1 26May 07, 26 | 8:00 AM
Q4 25Feb 24, 26 | 8:00 AM
Q3 25Nov 06, 25 | 8:00 AM

Peer Comparison


TickerCompany
QUREuniQure N.V.
OCULOcular Therapeutix, Inc.
RCUSArcus Biosciences, Inc.
DNLIDenali Therapeutics Inc.
MESOMesoblast Limited
COGTCogent Biosciences, Inc.
IBRXImmunityBio, Inc.
GPCRStructure Therapeutics Inc.
VRDNViridian Therapeutics, Inc.